SHH:688089
Cabio Biotech (Wuhan) Co., Ltd. · SHH · Healthcare · CNY · FY for 2025
Figures on this page computed 2026-11-08 13:17 UTC
Last close
n/aCNY
Market data
8.9xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
2.8%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
- Growth11.7%49 of 100, above its sector
- Returns on capital8.8%74 of 100, above its sector
- Marginsn/anot placed
- Price8.9x69 of 100, above its sector
- Safety4.4484 of 100, above its sector
- What it pays out2.8%63 of 100, above its sector
- Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
Then and now
lens 3 of 9| Fact | 2016 | 2025 | Change |
|---|---|---|---|
| Sales | 189,803,140 | 563,135,748 | +197% |
| Profit | 46,963,436 | 143,724,509 | +206% |
| Free cash flow | 46,325,940 | 125,532,855 | +171% |
| Debt | 40,000,000 | 83,193,518 | +108% |
| Shares in issue | 126,449,746 | 166,701,085 | +31.8% |
The same five facts for 2016 and 2025, each read from the year's own filing.
The same five facts for 2016 and 2025, each read from the year's own filing.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2016
Sales, 2016189,803,140
- Source
- computed
- Statement
- income
- Fiscal year
- 2016
- Reported in
- CNY
Sales, 2025563,135,748Computed from the filing for 2025
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Profit, 201646,963,436
- Source
- computed
- Statement
- income
- Fiscal year
- 2016
- Reported in
- CNY
Profit, 2025143,724,509Computed from the filing for 2025
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Free cash flow, 201646,325,940
- Source
- computed
- Statement
- income
- Fiscal year
- 2016
- Reported in
- CNY
Free cash flow, 2025125,532,855Computed from the filing for 2025
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Debt, 201640,000,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2016
- Reported in
- CNY
Debt, 202583,193,518Computed from the filing for 2025
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Shares in issue, 2016126,449,746
- Source
- computed
- Statement
- income
- Fiscal year
- 2016
- Reported in
- CNY
Shares in issue, 2025166,701,085Computed from the filing for 2025
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY